Liu Ying, Shen Jie, Zhang Xing, Ping Fan, Qyu Kai, Shen Xia
College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, China.
Shaanxi Qinling Application Development and Engineering Center of Chinese Herbal Medicine, Xi'an, 712046, China.
Chin J Integr Med. 2025 Jul 25. doi: 10.1007/s11655-025-4211-4.
To investigate the antidepressant effects of Xiaoyao Pill (XYP) by exploring its interactions with gut microbiota and tryptophan metabolism.
Utilizing network pharmacology, the functional substance groups, key targets, and pathways of XYP in the treatment of depression were identified. The chronic unpredictable mild stress (CUMS) protocol was implemented in male Sprague-Dawley rats to establish depression model. Thirty rats were randomly divided into 3 groups according to their body weight (10 for each): control, CUMS and XYP groups (1.8 g/kg). After 28-day interventions, behavioral phenotyping including sucrose preference test (SPT) and open field test (OFT) were performed. Biochemical validation encompassed enzyme-linked immunosorbent assay for serum cortisol, hematoxylin-eosin histopathology, and immunohistochemistry. Liquid chromatography-mass spectrometry was utilized to profile serum metabolites, while fecal samples underwent metagenomic sequencing for gut microbiota characterization.
Network pharmacology studies predicted that key components can protect the nervous system by regulating inflammatory pathways through the blood-brain barrier. SPT and OFT showed that XYP treatment significantly ameliorated depressive-like behaviors (all P<0.05). XYP treatment also restored hippocampal neuronal density, increased serum neurotransmitter levels of neurotransmitters such as 5-hydroxytryptamine and vasoactive intestinal peptide, and while suppressing inflammatory markers such as tumor necrosis factor-alpha, interleukin-1 beta (IL-1 β), and IL-6 (all P<0.05). Metagenomics revealed significant restructuring of gut microbiota, notably the regulation of Parabacteroides distasonis (P<0.05). Non-targeted metabolomics analysis showed that the level of metabolites in the tryptophan and kynurenine pathway significantly changed (variable importance in the projection >1, P<0.05), and the change of metabolic flux was significantly correlated with behavioral improvement (P<0.05).
XYP exerts antidepressant effects by increasing neurotransmitter levels, reducing inflammatory makers and modulating Parabacteroides distasonis. Through further exploration of metabolomics, we found that XYP may play a protective role in depression by regulating tryptophan metabolism.
通过探索逍遥丸(XYP)与肠道微生物群及色氨酸代谢的相互作用,研究其抗抑郁作用。
利用网络药理学,确定逍遥丸治疗抑郁症的功能物质组、关键靶点和通路。对雄性Sprague-Dawley大鼠实施慢性不可预测轻度应激(CUMS)方案以建立抑郁症模型。30只大鼠按体重随机分为3组(每组10只):对照组、CUMS组和逍遥丸组(1.8 g/kg)。经过28天干预后,进行行为表型分析,包括蔗糖偏好试验(SPT)和旷场试验(OFT)。生化验证包括血清皮质醇的酶联免疫吸附测定、苏木精-伊红组织病理学检查和免疫组织化学。利用液相色谱-质谱联用技术分析血清代谢物,同时对粪便样本进行宏基因组测序以表征肠道微生物群。
网络药理学研究预测,关键成分可通过血脑屏障调节炎症通路来保护神经系统。SPT和OFT结果显示,逍遥丸治疗显著改善了抑郁样行为(所有P<0.05)。逍遥丸治疗还恢复了海马神经元密度,提高了血清中5-羟色胺和血管活性肠肽等神经递质水平,同时抑制了肿瘤坏死因子-α、白细胞介素-1β(IL-1β)和IL-6等炎症标志物(所有P<0.05)。宏基因组学显示肠道微生物群发生了显著重组,尤其是对狄氏副拟杆菌的调节(P<0.05)。非靶向代谢组学分析表明,色氨酸和犬尿氨酸途径中的代谢物水平发生了显著变化(投影变量重要性>1,P<0.05),代谢通量的变化与行为改善显著相关(P<0.05)。
逍遥丸通过提高神经递质水平、降低炎症标志物和调节狄氏副拟杆菌发挥抗抑郁作用。通过进一步探索代谢组学,我们发现逍遥丸可能通过调节色氨酸代谢在抑郁症中发挥保护作用。